RUA Life Sciences PLC Appointment of Nominated Adviser and Broker (0094M)

TIDMRUA

RNS Number : 0094M

RUA Life Sciences PLC

19 May 2022

19 May 2022

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Appointment of Nominated Adviser and Sole Broker

RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the patented long-term implantable biostable polymer, announces it has appointed Cenkos Securities plc as the Company's nominated adviser and sole broker with immediate effect.

Cenkos Securities plc has been the Company's joint broker since December 2020.

For further information contact:

RUA Life Sciences plc

Bill Brown, Chairman Tel: [phone]

Caroline Stretton, Group Managing Director Tel: [phone]

Cenkos Securities plc (Nominated Adviser and Broker) Tel: [phone]

Giles Balleny/Max Gould (Corporate Finance)

Michael Johnson (Sales)

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon(TM) , the world's leading long-term implantable polyurethane.

Whether it is licensing Elast-Eon(TM) , manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and over 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

 
 RUA Medical :      End-to-end contract developer and manufacturer 
                     of medical devices and implantable fabric specialist. 
 RUA Biomaterials   Licensor of Elast-Eon(TM) polymers to the medical 
  :                  device industry. 
 RUA Vascular:      Commercialisation of open surgical vascular 
                     grafts and patches 
 RUA Structural     Development of polymeric leaflet systems for 
  Heart :            heart valves. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPAPMFTMTBBBLT

(END) Dow Jones Newswires

May 19, 2022 02:02 ET (06:02 GMT)